[ 18 F] MFBG PET imaging: biodistribution, pharmacokinetics, and comparison with [ 123 I] MIBG in neural crest tumour patients.

Autor: Pauwels E; Nuclear Medicine, University Hospitals Leuven, Campus Gasthuisberg, Herestraat 49, BE-3000, Leuven, Belgium.; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium., Celen S; Radiopharmaceutical research, Department of Pharmacy and Pharmacology, KU Leuven, Leuven, Belgium., Baete K; Nuclear Medicine, University Hospitals Leuven, Campus Gasthuisberg, Herestraat 49, BE-3000, Leuven, Belgium.; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium., Koole M; Nuclear Medicine, University Hospitals Leuven, Campus Gasthuisberg, Herestraat 49, BE-3000, Leuven, Belgium.; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium., Bechter O; General Medical Oncology, University Hospitals Leuven, Leuven, Belgium., Bex M; Endocrinology, University Hospitals Leuven, Leuven, Belgium., Renard M; Paediatric Oncology, University Hospitals Leuven, Leuven, Belgium., Clement PM; General Medical Oncology, University Hospitals Leuven, Leuven, Belgium., Jentjens S; Nuclear Medicine, University Hospitals Leuven, Campus Gasthuisberg, Herestraat 49, BE-3000, Leuven, Belgium.; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium., Serdons K; Nuclear Medicine, University Hospitals Leuven, Campus Gasthuisberg, Herestraat 49, BE-3000, Leuven, Belgium.; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium., Van Laere K; Nuclear Medicine, University Hospitals Leuven, Campus Gasthuisberg, Herestraat 49, BE-3000, Leuven, Belgium.; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium., Bormans G; Radiopharmaceutical research, Department of Pharmacy and Pharmacology, KU Leuven, Leuven, Belgium., Deroose CM; Nuclear Medicine, University Hospitals Leuven, Campus Gasthuisberg, Herestraat 49, BE-3000, Leuven, Belgium. christophe.deroose@uzleuven.be.; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium. christophe.deroose@uzleuven.be.
Jazyk: angličtina
Zdroj: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2023 Mar; Vol. 50 (4), pp. 1134-1145. Date of Electronic Publication: 2022 Nov 26.
DOI: 10.1007/s00259-022-06046-7
Abstrakt: Purpose: Despite its limitations, [ 123 I]MIBG scintigraphy has been the standard for human norepinephrine transporter (hNET) imaging for several decades. Recently, [ 18 F]MFBG has emerged as a promising PET alternative. This prospective trial aimed to evaluate safety, biodistribution, tumour lesion pharmacokinetics, and lesion targeting of [ 18 F]MFBG and perform a head-to-head comparison with [ 123 I]MIBG in neural crest tumour patients.
Methods: Six neural crest tumour patients (4 phaeochromocytoma, 1 paraganglioma, 1 neuroblastoma) with a recent routine clinical [ 123 I]MIBG scintigraphy (interval: - 37-75 days) were included. Adult patients (n = 5) underwent a 30-min dynamic PET, followed by 3 whole-body PET/CT scans at 60, 120, and 180 min after injection of 4 MBq/kg [ 18 F]MFBG. One minor participant underwent a single whole-body PET/CT at 60 min after administration of 2 MBq/kg [ 18 F]MFBG. Normal organ uptake (SUV mean ) and lesion uptake (SUV max ; tumour-to-background ratio (TBR)) were measured. Regional distribution volumes (V T ) were estimated using a Logan graphical analysis in up to 6 lesions per patient. A lesion-by-lesion analysis was performed to compare detection ratios (DR), i.e. fraction of detected lesions, between [ 18 F]MFBG and [ 123 I]MIBG.
Results: [ 18 F]MFBG was safe and well tolerated. Its biodistribution was overall similar to that of [ 123 I]MIBG, with prominent uptake in the salivary glands, liver, left ventricle wall and adrenals, and mainly urinary excretion. In the phaeochromocytoma subgroup, the median V T was 37.4 mL/cm 3 (range: 18.0-144.8) with an excellent correlation between V T and SUV mean at all 3 time points (R 2 : 0.92-0.94). Mean lesion SUV max and TBR at 1 h after injection were 19.3 ± 10.7 and 23.6 ± 8.4, respectively. All lesions detected with [ 123 I]MIBG were also observed with [ 18 F]MFBG. The mean DR with [ 123 I]MIBG was significantly lower than with [ 18 F]MFBG (61.0% ± 26.7% vs. 99.8% ± 0.5% at 1 h; p = 0.043).
Conclusion: [ 18 F]MFBG is a promising hNET imaging agent with favourable imaging characteristics and improved lesion targeting compared with [ 123 I]MIBG scintigraphy.
Trial Registration: Clinicaltrials.gov : NCT04258592 (Registered: 06 February 2020), EudraCT: 2019-003872-37A.
(© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje